Inverse vaccination, the opposite of Jenner's concept, for therapy of autoimmunity: Foresight

Journal of Internal Medicine

Volumn 267, Issue 5, 2010, Pages 441-451

  Steinman, L ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

Autoimmunity; Diabetes mellitus; Jenner; Multiple sclerosis; Vaccination

Indexed keywords

ALEMTUZUMAB; ATORVASTATIN; AUTOANTIGEN; CPG OLIGODEOXYNUCLEOTIDE; DNA VACCINE; GAMMA INTERFERON; INSULIN; INTERLEUKIN 4; MONOCLONAL ANTIBODY CD3; MYELIN; MYELIN BASIC PROTEIN; NATALIZUMAB; PLACEBO; PROINSULIN; PROTEOLIPID; RITUXIMAB; SMALLPOX VACCINE; T LYMPHOCYTE RECEPTOR;

ADAPTIVE IMMUNITY; ALLERGIC ENCEPHALOMYELITIS; ANTIGEN SPECIFICITY; AUTOIMMUNE DISEASE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CYTOKINE PRODUCTION; DRUG TARGETING; GRAFT REJECTION; GRAVES DISEASE; HASHIMOTO DISEASE; HEMATOLOGIC MALIGNANCY; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNE RESPONSE; INHIBITION KINETICS; INSULIN DEPENDENT DIABETES MELLITUS; MULTIPLE SCLEROSIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RASH; REVIEW; SMALLPOX; SMALLPOX VIRUS; T LYMPHOCYTE; VIRUS INFECTION;

ANIMALS; AUTOANTIBODIES; AUTOIMMUNE DISEASES; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS; DNA, BACTERIAL; HISTORY, 18TH CENTURY; HUMANS; MICE; MULTIPLE SCLEROSIS; OLIGONUCLEOTIDES; VACCINATION; VACCINES, DNA;

EID: 77950491480     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2010.02224.x     Document Type: Review

References (44)

1. Jenner E. The Three Original Publications on Vaccination against Smallpox, The Harvard Classics.
2. Garren H. DNA vaccines for autoimmune vaccines. Expert Rev Vaccines 2009 8 : 1195 1203.
3. Hauser SL, Waubant E, Arnold DL et al. B-cell depletion with Riutximab in relapsing-remitting multiple sclerosis. N Engl J Med 2009 358 : 676 688. (Pubitemid 351240747)
4. Food and Drug Administration. FDA Public Health Advisory: Life-Threatening Brain Infection in Patients with Systemic Lupus Erythematosus after Rituxan (Rituximab) Treatment.
5. Cohen SB, Emery P, Greenwald MW et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factory therapy: results of a multicenter, randomized, double-blind, placebo-controlled, Phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006 54 : 2793 2806. (Pubitemid 44497758)
6. The CAMMS223 Trial Investigators. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 2008 359 : 1786 1801.
7. Coles AJ, Wing M, Smith S et al. Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet 1999 354 : 1691 1695. (Pubitemid 29533060)
8. Keymeulen B, Candon S, Fafi-Kremer S et al. Transient Epstein Barr virus reactivation in CD3 monoclonal antibody-treated patients. Blood 2010 115 : 1145 1155.
9. Herold KC, Hagopian W, Auger JA et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 2002 346 : 1692 1698. (Pubitemid 34547482)
10. Keymeulen B, Vandemeulebroucke E, Ziegler AG et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005 352 : 2598 2608. (Pubitemid 41007846)
11. Polman CH, O'Connor PW, Havrdova E et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006 354 : 899 910. (Pubitemid 43313657)
12. Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005 353 : 375 381. (Pubitemid 41132342)
13. Steinman L. Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab. Nat Rev Drug Discov 2005 4 : 510 519. (Pubitemid 40861993)
14. Linda H, von Heijne A, Major ED et al. Progressive multifocal leukoencephalopathy after natalizumab monotherapy. N Engl J Med 2009 361 : 1081 1087.
15. Kappos L, Antel J, Comi G et al. Oral fingolimod [FTY720] for relapsing multiple sclerosis. N Engl J Med 2006 355 : 1124 1140. (Pubitemid 44394919)
16. Robinson WH, DiGennaro C, Hueber W et al. Antigen arrays for multiplex characterization of autoantibody responses. Nat Med 2002 8 : 295 301. (Pubitemid 34250109)
17. Robinson WH, Fontoura P, Lee BJ et al. Reverse genomics: protein microarrays guide tolerizing DNA vaccine treatment of autoimmune encephalomyelitis. Nat Biotechnol 2003 21 : 1033 1039. (Pubitemid 37064732)
18. Kanter J, Narayana S, Ho P et al. Lipid microarrays identify key mediators of autoimmune brain inflammation. Nat Med 2006 12 : 138 143. (Pubitemid 43050089)
19. Ousman SS, Tomooka BH, Van Noort JM et al. Protective and therapeutic role for aB-crystallin in autoimmune demyelination. Nature 2007 448 : 474 479.
20. Wolff JA, Malone RW, Williams P et al. Direct gene transfer into mouse muscle in vivo. Science 1990 247 : 1465 1468. (Pubitemid 20145055)
21. Ulmer JB, Donnelly JJ, Parker SE et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993 259 : 1745 1749. (Pubitemid 23114660)
22. Smith JM, Amara RR, McClure HM et al. Multiprotein HIV type 1 clade B DNA/MVA vaccine: construction, safety, and immunogenicity in Macaques. AIDS Res Hum Retroviruses 2004 20 : 654 665.
23. Osinubi MO, Wu X, Franka R et al. Enhancing comparative rabies DNA vaccine effectiveness through glycoprotein gene modifications. Vaccine 2009 27 : 7214 7218.
24. Martin JE, Sullivan NJ, Enama ME et al. A DNA vaccine for Ebola virus is safe and immunogenic in a Phase I clinical trial. Clin Vaccine Immunol 2006 13 : 1267 1277.
25. Waisman A, Ruiz PJ, Hirschberg DL et al. Suppressive vaccination with DNA encoding a variable region gene of the T cell receptor prevents autoimmune encephalomyelitis and activates Th2 immunity. Nat Med 1996 2 : 899 906. (Pubitemid 26296761)
26. Lobell A, Weissert R, Storch MK et al. Vaccination with DNA encoding an immunodominant myelin basic protein peptide targeted to Fc of immunoglobulin G suppresses experimental autoimmune encephalomyelitis. J Exp Med 1998 187 : 1543 1548. (Pubitemid 28215413)
27. Ruiz P, Garren H, Ruiz I et al. Suppressive immunization with DNA encoding a self-peptide prevents autoimmune disease: modulation of T cell co-stimulation. J Immunol 1999 162 : 3336 3341. (Pubitemid 29313582)
28. Garren H, Ruiz P, Watkins TA et al. Combination of gene delivery and DNA vaccination to protect from and reverse Th1 autoimmune disease via deviation to the Th2 pathway. Immunity 2001 15 : 15 22. (Pubitemid 32728316)
29. Krieg AM, Yi AK, Matson S et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995 374 : 546 549.
30. Sato Y, Roman M, Tighe H et al. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science 1996 273 : 352 354. (Pubitemid 26250262)
31. Tsunoda I, Tolley ND, Theil DJ, Whitton JL, Kobayashi H, Fujinami RS. Exacerbation of viral and autoimmune animal models for multiple sclerosis by bacterial DNA. Brain Pathol 1999 9 : 481 493. (Pubitemid 29316288)
32. Lobell A, Weissert R, Eltayeb S, de Graaf KL et al. Suppressive DNA vaccination in myelin oligodendrocyte glycoprotein peptide-induced experimental autoimmune encephalomyelitis involves a T1-biased immune response. J Immunol 2003 170 : 1806 1813. (Pubitemid 36197396)
33. Steinman L. A brief history of TH17, the first major revision in the TH1/TH2 hypothesis of T cell-mediated tissue damage. Nat Med 2007 13 : 139 145.
34. Voorthuis JA, Uitdehaag BM, De Groot CJ, Goede PH, van der Meide PH, Dijkstra CD. Suppression of experimental allergic encephalomyelitis by intraventricular administration of interferon-gamma in Lewis rats. Clin Exp Immunol 1990 81 : 183 188. (Pubitemid 20242519)
35. Panitch HS, Hirsch RL, Schindler J, Johnson KP. Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activation of the immune system. Neurology 1987 37 : 1097 1102. (Pubitemid 17123439)
36. Segal BM, Chang JT, Shevach EM. CpG oligonucleotides are potent adjuvants for the activation of autoreactive encephalitogenic T cells in vivo. J Immunol 2000 164 : 5683 5688.
37. Boccaccio G, Mor F, Steinman L. Non-coding plasmid DNA induced gamma interferon in vivo and suppresses autoimmune encephalomyelitis. Int Immunol 1999 11 : 289 296. (Pubitemid 29074103)
38. Ho P, Fontoura P, Ruiz P, Steinman L, Garren H. An immunomodulatory GpG oligonucleotide for the treatment of autoimmunity via the innate and adaptive immune systems. J Immunol 2003 171 : 4920 4926. (Pubitemid 37310616)
39. Ho P, Fontoura P, Platten M et al. A suppressive oligodeoxynucleotide enhances the efficacy of myelin cocktail/IL-4 tolerizing DNA vaccination and treats autoimmune disease. J Immunol 2005 175 : 6226 6234. (Pubitemid 41508112)
40. Urbanek-Ruiz I, Ruiz P, Garren H et al. Immunization with DNA encoding an immunodominant peptide of insulin prevents diabetes in NOD mice. Clin Immunol 2001 100 : 164 171. (Pubitemid 32703421)
41. Solvason N, Lou YP, Peters W et al. Improved efficacy of a tolerizing DNA vaccine for reversal of hyperglycemia through enhancement of gene expression and localization to intracellular sites. J Immunol 2008 181 : 8298 8307.
42. Bar-Or A, Vollmer T, Antel J et al. Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled Phase 1-2 trial. Arch Neurol 2007 64 : 1407 1415. (Pubitemid 47572664)
43. Garren H, Robinson W, Krasulová E et al. Phase 2b trial of a DNA vaccine encoding myelin basic protein in relapsing multiple sclerosis. Ann Neurol 2008 63 : 611 620.
44. Young D. Bayhill Therapeutics snags $350 million deal with Genentech. Bioworld Today 2009 20 : 1.